RSS   Newsletter   Contact   Advertise with us

Unprecedented discovery: Roche drug cocktail doubles chance of holding lung cancer at bay

Share on Twitter Share on LinkedIn
Staff Writer | December 9, 2017
Adding Roche’s immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing.
Tumors   Tecentriq and Avastin plus chemotherapy
This is an outcome some experts on Thursday labeled unprecedented.

Thirty-seven percent of patients in Roche’s clinical trial who got Tecentriq, Avastin and chemotherapy reached the one-year mark without their cancer progressing (PFS).

For patients getting just Avastin and chemotherapy in the Impower 150 study, that fell to 18 percent.

"The study showed that people who received Tecentriq and Avastin plus chemotherapy had a 38 percent reduced risk of their disease worsening or death (progression-free survival, PFS) compared with those who received Avastin plus chemotherapy...

"Importantly, a doubling of the 12-month landmark PFS rate was observed with the combination of Tecentriq and Avastin plus chemotherapy (37 percent) compared to Avastin plus chemotherapy (18 percent)," the company said.

"The rate of tumour shrinkage (overall response rate, ORR), a secondary endpoint in the study, was higher in people treated with Tecentriq and Avastin plus chemotherapy compared with Avastin plus chemotherapy (64 percent vs. 48 percent).

"The safety profile of the Tecentriq and Avastin plus chemotherapy combination was consistent with the safety profiles of the individual medicines, and no new safety signals were identified with the combination."